Low-grade glioma with novel mutations in KRAS and PMS2 in an adolescent with Down syndrome

Jason W Adams,1 Denise Malicki,2 Michael Levy,3 John Ross Crawford4

DESCRIPTION
A 12-year-old boy with Down syndrome (DS), myeloproliferative disorder and autism spectrum disorder presented for new-onset seizures. The patient did not report any headaches, weakness, nausea or vomiting, and neurological examination was non-focal. MRI revealed a mixed solid and cystic 13 mm mass with surrounding vasogenic oedema immediately lateral to the posterior horn of the left lateral ventricle in the periatrial white matter (figure 1). The mass lesion was similar in appearance to the adjacent choroid plexus cyst and demonstrated contrast enhancement without reduced diffusivity. Neuroradiographic differential diagnosis included low-grade astrocytoma, gangliocytoma or ganglioglioma. The patient underwent robotic-guided biopsy and laser ablation. Neuropathology revealed a hypercellular tumour with angiocentric proliferation consisting of spindle-shaped to ovoid-shaped cells with pale cytoplasmic nuclei and scattered inclusions. Denser areas of the neoplasm, comprising astrocytes with a dense fibrillar matrix, contrasted with looser areas consisting of more widely spaced cells separated by an oedematous to myxoid stroma (figure 2). Scattered Rosenthal fibres and eosiaphilic granular bodies were observed, as well as rare mitotic figures. No significant necrosis was appreciated. Immunohistochemistry showed diffuse positivity for glial fibrillar acidic protein and weak positivity for synaptophysin. Sparse (1%–2%) tumour nuclei stained Ki67+. Immunostaining for epithelial membrane antigen was negative. Next-generation sequencing (NGS) revealed three novel clinically significant variants, two in KRAS (c.64C>G and c.353G>C) and one in PMS2 (c.5382A>G). NGS likewise detected multiple variants of unknown clinical significance, within genes including TAF1, RARA, DNMT3A, ITK, KIF5B, CHD4, AKT1 and GRIN2A; no BRAF mutation or fusion was detected. Microarray analysis was consistent with constituent trisomy 21 but otherwise detected no clinically significant abnormalities. The complete neuropathological profile was most consistent with a diagnosis of low-grade glioma (WHO grade I), histologically favouring pilocytic astrocytoma. Follow-up imaging has shown no evidence of residual or recurrent tumour within 18 months after laser ablation, and the patient remains seizure-free on anticonvulsant medication.

DS is associated with an altered neoplastic risk profile and may influence the frequency of particular types of brain tumours.1–8 Cases of glioma in DS occur rarely,9 10 11 and whether DS affects glioma behaviour is unclear. We present a rare case of low-grade glioma with novel KRAS and PMS2 mutations in an adolescent with DS. Low-grade gliomas nearly exclusively harbour mutations that upregulate the Ras/MAPK pathway.12–15 Of these, only a slight proportion (<1%) involves the pathway effector KRAS,16 hinting at the dual novel KRAS mutations observed in the present case. Mutation of the DNA mismatch repair gene PMS2 has previously been documented in hypermutated paediatric high-grade glioma,17 suggesting that its...
mutation in the low-grade neoplasm here may be permissive of mutational burden. Future investigation should further explore the mutational landscape of glioma in DS.

**Learning points**

- Low-grade gliomas are nearly universally associated with mutations in the Ras/MAPK pathway, but mutations in KRAS comprise a very small proportion (<1%)
- The occurrence of central nervous system tumours in association with Down syndrome is rare, and the mechanism of the role, if any, for trisomy 21 is unclear.
- We report the case of low-grade glioma with a unique molecular profile in association with Down syndrome, expanding the genetic complexity of low-grade glioma.

**Contributors** JWA, DM, ML and JRC were responsible for the design and creation of the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


